<p>Redcare Pharmacy NV reported preliminary sales figures for the fourth quarter and full year 2025. The Group achieved Q4 sales of EUR 794 million, an 18% increase compared to EUR 675 million in Q4 2024. Full year sales rose 24% to EUR 2.9 billion, up from EUR 2.4 billion in 2024. In Germany, prescription (Rx) sales nearly doubled, increasing 98% from EUR 254 million in 2024 to EUR 503 million in 2025. Overall Rx sales in the DACH region (Germany, Austria, Switzerland) grew by 33.9% in Q4 to EUR 311 million, and full-year Rx sales reached EUR 1 billion, up from EUR 750 million in 2024. Non-Rx sales in Q4 increased 9% to EUR 483 million, with full-year non-Rx sales up 15% to EUR 1.9 billion. The number of active customers rose by 1.4 million year over year to 13.9 million. Customer satisfaction, measured by the Net Promoter Score, averaged 74 in Q4 and 68 for the full year, compared to 69 in 2024. Sales in the International segment, which includes Belgium, Italy, France, and the Netherlands, grew 17.9% in Q4 to EUR 138 million and 23.7% for the full year to EUR 540 million. All figures are preliminary and unaudited. The company plans to release its Annual Report for 2025 on March 4, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redcare Pharmacy NV published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Redcare Pharmacy NV Reports 24% Rise in 2025 Sales to EUR 2.9 Billion